Citadel Advisors’s Adial Pharmaceuticals ADIL Stock Holding History

Citadel Advisors’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$75.6K	Buy	+29,547	New	+$58.5K	﹤0.01%	12873
2026 Q1	–	Sell	-8,785	Closed	-$48.3K	–	12872
2025 Q4	$48.3K	Buy	8,785 +3,033	+53%	+$24.6K	﹤0.01%	12053
2025 Q3	$50.8K	Buy	+5,752	New	+$56.1K	﹤0.01%	12196
2025 Q1	–	Sell	-2,180	Closed	-$55.1K	–	14378
2024 Q4	$55.1K	Buy	2,180 +849	+64%	+$22.1K	﹤0.01%	12294
2024 Q3	$33.2K	Buy	1,331 +341	+34%	+$8.89K	﹤0.01%	12335
2024 Q2	$28.5K	Buy	+990	New	+$37.4K	﹤0.01%	12319
2022 Q4	–	Sell	-424	Closed	-$93K	–	14822
2022 Q3	$93K	Buy	+424	New	+$191K	﹤0.01%	11150
2021 Q3	–	Sell	-32	Closed	-$52K	–	13721
2021 Q2	$52K	Sell	32 -87	-73%	-$132K	﹤0.01%	13321
2021 Q1	$180K	Sell	119 -4	-3%	-$6.04K	﹤0.01%	11826
2020 Q4	$131K	Buy	+123	New	+$145K	﹤0.01%	10033
2019 Q2	–	Sell	-42	Closed	-$91K	–	9094
2019 Q1	$91K	Buy	+42	New	+$125K	﹤0.01%	8589

Other funds holding ADIL

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCM

Manchester Capital Management Manchester, Vermont $768M AUM 29.32% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors's ADIL Position: Q2 2026 in Review

Citadel Advisors opened a new position in Adial Pharmaceuticals (ADIL) in Q2 2026: 29,547 shares worth $75.6K. The stake represents ﹤0.01% of the portfolio and ranks #12873 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ADIL as recently as Q4 2025.

Citadel Advisors first reported a position in ADIL in Q1 2019 and has held it in 11 quarters since. The position peaked at $180K in Q1 2021. 17 funds tracked by Wall St. Rank hold ADIL as of Q2 2026.

Citadel Advisors held 29,547 shares of Adial Pharmaceuticals worth $75.6K as of Q2 2026.
Adial Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
Adial Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12873 holding.
Citadel Advisors first reported a position in Adial Pharmaceuticals in Q1 2019 and has held it in 11 quarters since.
Citadel Advisors's Adial Pharmaceuticals position peaked at $180K in Q1 2021.
17 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.